ABSTRACT
Cardio-facio-cutaneous syndrome (CFCS) is a rare disorder characterized by distinctive craniofacial appearance, cardiac, neurologic, cutaneous, and musculoskeletal abnormalities. It is due to heterozygous mutations in BRAF, MAP2K1, MAP2K2, and KRAS genes, belonging to the RAS/MAPK pathway. The role of RAS signaling in bone homeostasis is highly recognized, but data on bone mineral density (BMD) in CFCS are lacking. In the present study we evaluated bone parameters, serum and urinary bone metabolites in 14 individuals with a molecularly confirmed diagnosis of CFCS. Bone assessment was performed through dual X-ray absorptiometry (DXA); height-adjusted results were compared to age- and sex-matched controls. Blood and urinary bone metabolites were also analyzed and compared to the reference range. Despite vitamin D supplementation and almost normal bone metabolism biomarkers, CFCS patients showed significantly decreased absolute values of DXA-assessed subtotal and lumbar BMD (p ≤ 0.05), compared to controls. BMD z-scores and t-scores (respectively collected for children and adults) were below the reference range in CFCS, while normal in healthy controls. These findings confirmed a reduction in BMD in CFCS and highlighted the importance of monitoring bone health in these affected individuals.
Subject(s)
Ectodermal Dysplasia , Failure to Thrive , Absorptiometry, Photon , Adult , Bone Density/genetics , Child , Ectodermal Dysplasia/diagnosis , Ectodermal Dysplasia/genetics , Facies , Failure to Thrive/genetics , Heart Defects, Congenital , Homeostasis , HumansABSTRACT
Germline mutations in BRAF and other components of the MAPK pathway are associated with the congenital syndromes collectively known as RASopathies. Here, we report the association of Septo-Optic Dysplasia (SOD) including hypopituitarism and Cardio-Facio-Cutaneous (CFC) syndrome in patients harbouring mutations in BRAF. Phosphoproteomic analyses demonstrate that these genetic variants are gain-of-function mutations leading to activation of the MAPK pathway. Activation of the MAPK pathway by conditional expression of the BrafV600E/+ allele, or the knock-in BrafQ241R/+ allele (corresponding to the most frequent human CFC-causing mutation, BRAF p.Q257R), leads to abnormal cell lineage determination and terminal differentiation of hormone-producing cells, causing hypopituitarism. Expression of the BrafV600E/+ allele in embryonic pituitary progenitors leads to an increased expression of cell cycle inhibitors, cell growth arrest and apoptosis, but not tumour formation. Our findings show a critical role of BRAF in hypothalamo-pituitary-axis development both in mouse and human and implicate mutations found in RASopathies as a cause of endocrine deficiencies in humans.
Subject(s)
Gain of Function Mutation , Hypopituitarism/genetics , Hypothalamus/metabolism , Pituitary Gland/metabolism , Proto-Oncogene Proteins B-raf/genetics , Animals , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Cells, Cultured , Child , Child, Preschool , Corticotrophs/cytology , Corticotrophs/metabolism , Ectodermal Dysplasia/genetics , Facies , Failure to Thrive/genetics , HEK293 Cells , Heart Defects, Congenital/genetics , Humans , Infant , MAP Kinase Signaling System/genetics , Melanotrophs/cytology , Melanotrophs/metabolism , Mice, Knockout , Mice, Transgenic , Proto-Oncogene Proteins B-raf/metabolism , Exome Sequencing/methodsABSTRACT
BACKGROUND: Gabriele-de Vries syndrome (GADEVS), also known as YY1 haploinsufficiency syndrome, is a very rare autosomal dominant neurodevelopmental disorder (NDD) due to YY1 mutation characterized by mild-to-profound developmental delay (DD)/intellectual disability (ID), a wide spectrum of functional and morphologic abnormalities, and intrauterine growth restriction or low birth weight and feeding difficulties are common in the patients. However, NDDs, such as language development disorder and ID, could hardly be assessed in patients younger than 2 years old. METHODS: We describe a 9-month-old female with DD, failure to thrive, and facial dysmorphism. Genetic analysis was conducted by whole exome sequencing (WES) and confirmed by Sanger sequencing. RESULTS: In addition to DD and dysmorphic facial features, this patient had urinary tract infection, acute pyelonephritis, bilateral vesicoureteral reflux (grade III), gastroesophageal reflux, and malnutrition. She was found to have foramen ovale or atrial septal defect, and enlarged left lateral ventricle in the brain. After performing WES, a novel heterozygous mutation NM_003403.5:c.1124G>A, p.Arg375Gln in the YY1 gene was identified. CONCLUSION: Our findings suggest that genetic tests are critical technique for diagnosis of GADEVS, especially in patients with early-childhood, unexplained developmental or growth disorders, thus, the prevalence of GADEVS may be underestimated. The clinical features and identified YY1 mutation in our patient expand the spectra of phenotypes and genotypes of GADEVS, respectively.
Subject(s)
Craniofacial Abnormalities/genetics , Developmental Disabilities/genetics , Failure to Thrive/genetics , YY1 Transcription Factor/genetics , Craniofacial Abnormalities/pathology , Developmental Disabilities/pathology , Failure to Thrive/pathology , Female , Germ-Line Mutation , Haploinsufficiency , Humans , Infant , SyndromeABSTRACT
The VARS2 gene encodes a mitochondrial valyl-transfer RNA synthetase which is used in mitochondrial translation. To date, several patients with VARS2 pathogenic variants have been described in the literature. These patients have features of lactic acidosis with encephalomyopathy. We present a case of an infant with lactic acidosis, failure to thrive, and severe primary pulmonary hypertension who was found to be a compound heterozygote for two novel VARS2 variants (c.1940C>T, p.(Thr647Met) and c.2318G>A, p.(Arg773Gln)). The patient was treated with vitamin supplements and a carbohydrate-restricted diet. The lactic acidosis and failure to thrive resolved, and he showed good growth and development. Functional studies and molecular analysis employed a yeast model system and the VAS1 gene (yeast homolog of VARS2). VAS1 genes harboring either one of two mutations corresponding to the two novel variants in the VARS2 gene, exhibited partially reduced function in haploid yeast strains. A combination of both VAS1 variant alleles in a diploid yeast cell exhibited a more significant decrease in oxidative metabolism-dependent growth and in the oxygen consumption rate (reminiscent of the patient who carries two mutant VARS2 alleles). Our results demonstrate the pathogenicity of the biallellic novel VARS2 variants. KEY MESSAGES: ⢠A case of an infant who is a compound heterozygote for two novel VARS2 variants. ⢠This infant displayed lactic acidosis, failure to thrive, and pulmonary hypertension. ⢠Treatment of the patient with a carbohydrate-restricted diet resulted in good growth and development. ⢠Studies with the homologous yeast VAS1 gene showed reduced function of corresponding single mutant in haploid yeast strains. ⢠A combination of both VAS1 variant alleles in diploid yeast exhibited a more significant decrease in function, thereby confirming the pathogenicity of the biallellic novel VARS2 variants.
Subject(s)
Failure to Thrive/genetics , Failure to Thrive/metabolism , HLA Antigens/genetics , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/metabolism , Mitochondrial Diseases/genetics , Mitochondrial Diseases/metabolism , Valine-tRNA Ligase/genetics , Alleles , Amino Acid Sequence , Heterozygote , Humans , Infant , Male , Mutation/genetics , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Sequence Analysis, DNAABSTRACT
COX5A is a nuclear-encoded subunit of mitochondrial respiratory chain complex IV (cytochrome c oxidase). We present patients with a homozygous pathogenic variant in the COX5A gene. Clinical details of two affected siblings suffering from early-onset pulmonary arterial hypertension, lactic acidemia, failure to thrive, and isolated complex IV deficiency are presented. We show that the variant lies within the evolutionarily conserved COX5A/COX4 interface domain, suggesting that it alters the interaction between these two subunits during complex IV biogenesis. In patient skin fibroblasts, the enzymatic activity and protein levels of complex IV and several of its subunits are reduced. Lentiviral complementation rescues complex IV deficiency. The monomeric COX1 assembly intermediate accumulates demonstrating a function of COX5A in complex IV biogenesis. A potential therapeutic lead is demonstrated by showing that copper supplementation leads to partial rescue of complex IV deficiency in patient fibroblasts.
Subject(s)
Acidosis, Lactic/genetics , Cyclooxygenase 1/genetics , Cytochrome c Group/genetics , Failure to Thrive/genetics , Hypertension, Pulmonary/genetics , Acidosis, Lactic/pathology , Cell Nucleus/genetics , Cyclooxygenase 1/chemistry , Cytochrome c Group/chemistry , Cytochrome-c Oxidase Deficiency , Electron Transport Complex IV , Failure to Thrive/pathology , Fibroblasts , Genetic Predisposition to Disease , Homozygote , Humans , Hypertension, Pulmonary/pathology , Mitochondria/genetics , Mutation , Protein Subunits/geneticsABSTRACT
Pseudohypoaldosteronism type 1 (PHA1) is a rare condition characterized by neonatal salt loss with elevated plasma aldosterone and renin levels. Two types of PHA1 have been described: an autosomal recessive systemic form and an autosomal dominant renal form, in which the target organ defect is confined to the renal tubules. The dominant renal form of PHA1 is caused by heterozygous mutations in the NR3C2 gene, which encodes the mineralocorticoid receptor (MR). We determined clinical and biochemical parameters in two familial and four sporadic Japanese patient and analyzed the status of the NR3C2 gene. Failure to thrive was noted in five of the six patients. In one of the familial cases, the mother had an episode of failure to thrive when she was a toddler, but received no medical treatment. NaCl supplementation was discontinued in four of the six patients after they reached one year of age and they have grown normally thereafter. However, in one patient, 9 g/day of salt has been required to maintain serum Na concentration after 1 year of age. Analysis of NR3C2 identified three novel mutations [c. C1951T (p.R651X), c.304_305delGC (p.A102fsX103), c.del 603A (p.T201fsX34)] and one previously reported mutation [c.A2839G (p.947X)]. p.R651X was identified in one familial case and one unrelated sporadic patient. The patient who has been supplemented with large amount of salt was heterozygous for c.del 603A in exon 2. In conclusion, our study expands the spectrum of phenotypes, and characterized mutations of NR3C2 in the renal form of PHA1.
Subject(s)
Kidney Tubules/physiopathology , Pseudohypoaldosteronism/genetics , Pseudohypoaldosteronism/physiopathology , Aldosterone/blood , Failure to Thrive/genetics , Female , Heterozygote , Humans , Infant , Infant, Newborn , Japan , Male , Mutation , Phenotype , Pseudohypoaldosteronism/therapy , Receptors, Mineralocorticoid/genetics , Renin/blood , Sodium Chloride/administration & dosageABSTRACT
We report on a boy, born on term, presenting with a weight loss and a persistent failure to thrive after 10 days despite a normal behavior under bottle-feeding. The clinical examination was normal and biological assessment revealed hyponatremia with hyponatriuria, normal kaliemia and elevated aldosterone values, leading to type I pseudohypoaldosteronism diagnosis. Treatment with salt supplementation allowed growth improvement. The diagnosis was confirmed by the identification of a mutation in the mineralocorticoid receptor. This change was also found in several family members.
Subject(s)
Failure to Thrive/etiology , Failure to Thrive/genetics , Pseudohypoaldosteronism/complications , Pseudohypoaldosteronism/genetics , Humans , Infant, Newborn , Male , PedigreeABSTRACT
Chylomicron retention disease (CRD), or Anderson disease, is a rare, hereditary cause of fat malabsorption. It is one of the familial hypocholesterolaemia syndromes, along with homozygous hypobetalipoproteinaemia (HBL) and abetalipoproteinaemia (ABL). We report clinical, laboratory and histological data as well as molecular DNA analysis in the case of a 4-month-old boy with failure to thrive and steatorrhea who was diagnosed with CRD. His mother's first cousin, who was diagnosed as hypobetalipoproteinaemia 30 years ago, was also reviewed and his diagnosis was revised to CRD. Both patients were treated with a low fat diet and supplementation with fat-soluble vitamins resulting in significant improvement. In conclusion, CRD is a well-defined cause of fat malabsorption and can be distinguished from other forms of familial hypocholesterolaemia because of its specific lipid profile.
Subject(s)
Chylomicrons/metabolism , Failure to Thrive/diagnosis , Growth Disorders/diagnosis , Lipid Metabolism Disorders/diagnosis , Malabsorption Syndromes/diagnosis , Diet, Fat-Restricted , Dietary Supplements , Duodenum/pathology , Duodenum/ultrastructure , Endoscopy, Gastrointestinal , Failure to Thrive/genetics , Failure to Thrive/metabolism , Family Health , Growth Disorders/genetics , Growth Disorders/metabolism , Humans , Infant , Lipid Metabolism Disorders/genetics , Lipid Metabolism Disorders/metabolism , Malabsorption Syndromes/genetics , Malabsorption Syndromes/metabolism , Male , Steatorrhea/diagnosis , Steatorrhea/genetics , Steatorrhea/metabolism , Vitamins/administration & dosageABSTRACT
Acrodermatitis enteropathica (AE) is a rare autosomal-recessive disorder characterized by dermatitis, alopecia, diarrhea, and retardation of growth and development. AE maps to 8q24.3 and is associated with mutations in the intestinal zinc transporter ZIP4 encoded by the gene SLC39A4. We describe a novel homozygous mutation, 1191insC, in SLC39A4 in a patient from Sierra Leone and suggest that AE should be considered within the differential diagnosis for acrodermatitis in children from Sierra Leone. Genetic testing for this founder mutation can be easily performed for this treatable disorder.
Subject(s)
Acrodermatitis/genetics , Cation Transport Proteins/genetics , Mutation , Acrodermatitis/drug therapy , Alopecia/drug therapy , Alopecia/genetics , Diarrhea/drug therapy , Diarrhea/genetics , Dietary Supplements , Failure to Thrive/diagnosis , Failure to Thrive/genetics , Female , Homozygote , Humans , Infant , Treatment Outcome , Zinc/blood , Zinc/deficiency , Zinc Sulfate/therapeutic useABSTRACT
3-Methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine catabolism. MCC is a heteromeric mitochondrial enzyme composed of biotin-containing alpha (MCCA) and smaller beta (MCCB) subunits encoded by MCCA and MCCB, respectively. We report studies of the c.1054G-->A mutation in exon 11 of MCCB detected in the homozygous state in a patient with MCC deficiency. Sequence analysis of MCCB cDNA revealed two overlapping transcripts, one containing the normal 73 bp of exon 11 including the missense mutation c.1054G-->A (p.G352R), the other with exon 11 replaced by a 64-bp sequence from intron 10 (cryptic exon 10a) that maintains the reading frame and is flanked by acceptable splice consensus sites. In expression studies, we show that both transcripts lack detectable MCC activity. Western blot analysis showed slightly reduced levels of MCCB using the transcript containing the missense mutation, whereas no MCCB was detected with the transcript containing the cryptic exon 10a. Analysis of the region harboring the mutation revealed that the c.1054G-->A mutation is located in an exon splice enhancer sequence. Using MCCB minigene constructs to transfect MCCB-deficient fibroblasts, we demonstrate that the reduction in utilization of exon 11 associated with the c.1054G-->A mutation is due to alteration of this exon splice enhancer. Further, we show that optimization of the weak splice donor site of exon 11 corrects the splicing defect. To our knowledge, this is the first demonstration of a point mutation disrupting an exon splice enhancer that causes exon skipping along with utilization of a cryptic exon.
Subject(s)
Amino Acid Metabolism, Inborn Errors/genetics , Carbon-Carbon Ligases/deficiency , Carbon-Carbon Ligases/genetics , Alternative Splicing , Consanguinity , DNA Mutational Analysis , DNA, Complementary/metabolism , Exons , Failure to Thrive/genetics , Fibroblasts/metabolism , Humans , Models, Genetic , Mutation , Mutation, Missense , Sequence Analysis, DNA , Skin/metabolismABSTRACT
CONTEXT: The type 1 IGF-I receptor (IGF1R) mediates the biological functions of IGF-I. Binding of IGF-I to the IGF1R results in autophosphorylation of the intracellular beta-subunit and activation of intracellular signaling. OBJECTIVE: The objective of this study was to evaluate the functional characteristics of a novel IGF1R mutation and describe the phenotypic features of two patients with this mutation. DESIGN: The study was performed in a university hospital. PATIENTS: We describe a 35-yr-old female with mild intrauterine growth failure, progressive postnatal growth retardation, severe failure to thrive, and microcephaly. Her daughter was born with severe intrauterine growth retardation and also showed postnatal failure to thrive and microcephaly. RESULTS: We found a heterozygous G3148-->A nucleotide substitution in the IGF1R gene, changing a negatively charged glutamic acid at position 1050 into a positively charged lysine residue (E1050K). E1050 is a conserved residue in the intracellular kinase domain. Dermal fibroblasts of the mother showed normal binding of iodinated IGF-I, but autophosphorylation and activation of downstream signaling cascades upon challenging with IGF-I was markedly reduced. Consequently, the maximal [(3)H]thymidine incorporation upon challenge with a dose range of IGF-I was reduced compared with a panel of control cells (3.65 +/- 1.79-fold vs. 6.75 +/- 4.7-fold stimulation; P < 0.01). These data suggest that the mutation results in the inactivation of one copy of the IGF1R gene. CONCLUSIONS: These two patients support the key role for IGF-I in intrauterine and postnatal growth. The different phenotypes of these and earlier described patients may be associated with variability in IGF-I signaling. The degree of intrauterine growth retardation may be partially determined by the presence or absence of maternal IGF-I resistance.
Subject(s)
Fetal Growth Retardation/genetics , Growth Disorders/genetics , Mutation, Missense/genetics , Receptor, IGF Type 1/genetics , Adult , Base Sequence , Body Height , Bone Density , DNA Mutational Analysis , DNA, Complementary/chemistry , Failure to Thrive/genetics , Female , Fibroblasts/metabolism , Glutamic Acid , Heterozygote , Humans , Infant , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor I/pharmacology , Lysine , Microcephaly/genetics , Phosphorylation , Polymerase Chain Reaction , Receptor, IGF Type 1/physiology , Sequence Analysis, DNA , Signal Transduction/drug effectsABSTRACT
Dopamine (DA) controls a wide variety of physiological functions in the central nervous system as well as in the neuroendocrine and gastrointestinal systems. DA signaling is mediated by five cloned receptors named D1-D5. Knockout mouse models for the five receptors have been generated, and, albeit impaired for some important DA-mediated functions, they are viable and can reproduce. D1 and D2 receptors are the most abundant and widely expressed DA receptors. Cooperative/synergistic effects mediated by these receptors have been suggested, in particular, in the control of motor behaviors. To analyze the extent of such interrelationship, we have generated double D1/D2 receptor mutants. Interestingly, in contrast to single knockouts, we found that concurrent ablation of the D1 and D2 receptors is lethal during the second or third week after birth. This dramatic phenotype is likely to be related to altered feeding behavior and dysfunction of the gastrointestinal system, especially because major anatomical changes were not identified in the brain. Similarly, in the absence of functional D1, heterozygous D2 mutants (D1r(-/-);D2r(+/-)) showed severe growth retardation and did not survive their postweaning period. The analysis of motor behavior in D1r/D2r compound mutants showed that loss of D2-mediated functions reduces motor abilities, whereas the effect of D1r ablation on locomotion strongly depends on the experimental paradigms used. These studies highlight the interrelationship between D1 and D2 receptor-mediated control of motor activity, food intake, and gastrointestinal functions, which has been elusive in the single-gene ablation studies.
Subject(s)
Failure to Thrive/genetics , Failure to Thrive/physiopathology , Receptors, Dopamine D1/genetics , Receptors, Dopamine D2/genetics , Signal Transduction/physiology , Animals , Digestive System/physiopathology , Eating , Feeding Behavior , Female , Genes, Lethal , Hypothalamus/physiopathology , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Motor Neurons/physiology , Phenotype , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolismABSTRACT
Human mitochondrial DNA (mt DNA) lesions can cause a heterogeneous group of mitochondrial degenerative disorders. We report on a 5-year-old patient suffering from the full-blown picture of Pearson syndrome. His symptoms started in the first year of life with failure to thrive, followed by chronic diarrhoea and lactic acidosis at 18 months of age. Analysis of mitochondrial DNA revealed large amounts of mt DNA molecules with a 2.7 kb deletion in all tissues examined. The diagnosis of Pearson syndrome was made initially in the absence of haematological disturbances. In the following months neutropenia, sideroblastic anaemia and hypoparathyroidism developed. Daily administration of dichloroacetate (DCA) and bicarbonate controls the lactic acidosis, while episodic treatments with filgastrim (Neupogen) reverse episodes of severe neutropenia. Calcium and vitamin D supplementation compensate for the hypoparathyroidism. Chronic administration of DCA and supportive treatment for a long period help to stabilize patients with multiorgan dysfunction.
Subject(s)
Abnormalities, Multiple/genetics , Bone Marrow Diseases/genetics , DNA, Mitochondrial , Pancreatic Diseases/genetics , Sequence Deletion , Abnormalities, Multiple/drug therapy , Acidosis, Lactic/drug therapy , Acidosis, Lactic/genetics , Blotting, Southern , Bone Marrow Diseases/pathology , Child, Preschool , Diarrhea/drug therapy , Diarrhea/genetics , Failure to Thrive/genetics , Humans , Male , Pancreatic Diseases/drug therapy , Restriction Mapping , SyndromeABSTRACT
The case of a female preterm infant (gestational age 36 weeks) is described, who presented with abdominal distension, diarrhoea, dehydration and metabolic alkalosis at the fifth day of life. After different diagnostic tests had been performed, congenital chloride diarrhoea was suspected and chloride supplementation was started. However, this diagnosis could not be confirmed, until the measurement of electrolytes in faeces had been improved. Then, we found the typically elevated fecal chloride concentration (130-153 mmol/l) which exceeded the sum of the fecal concentration of sodium (64-90 mmol/l) and potassium (28-35 mmol/l). The chloride supplementation was increased to 6 mmol/kg/d NaCl and 2 mmol/kg/d KCl. The most recent examination at the age of 1 year revealed the girl to be in good clinical condition, with normal growth and psychomotor-development and with no evidence of renal impairment.